^
    2d
    ATTAIN: Daratumumab and Belatacept for Desensitization (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Darzalex (daratumumab)
    8d
    Venetoclax-based therapy in high-risk patients with relapsed/refractory multiple myeloma harboring t(11;14): a case report and review of the literature. (PubMed, J Med Case Rep)
    Venetoclax combination regimen achieved excellent efficacy and safety in the treatment of relapsed/refractory multiple myeloma with t(11;14) in this case. The treatment of patients with relapsed and refractory multiple myeloma with t(11;14) by venetoclax still needs to be confirmed by more clinical studies.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Darzalex (daratumumab) • dexamethasone
    9d
    Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • dexamethasone • sonrotoclax (BGB-11417)
    14d
    DREAMM-10: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (clinicaltrials.gov)
    P3, N=520, Recruiting, GlaxoSmithKline | Trial completion date: Apr 2032 --> Mar 2031 | Trial primary completion date: Dec 2030 --> Mar 2031
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    15d
    MagnetisMM-6: A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (clinicaltrials.gov)
    P3, N=1116, Recruiting, Pfizer | Trial completion date: Nov 2031 --> Oct 2033 | Trial primary completion date: Mar 2028 --> Oct 2030
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Elrexfio (elranatamab-bcmm)
    18d
    Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    The patients were categorized based on their treatment regimens into the bortezomib-based group (V, 37 cases), bortezomib + lenalidomide-based group (VR, 28 cases), and daratumumab + bortezomib + lenalidomide-based group (DVR, 75 cases). In the new drug era, different induction chemotherapy regimens significantly impact hematopoietic stem cell mobilization and collection, with lenalidomide and daratumumab exhibiting notable effects. Timely administration of plerixafor for salvage mobilization based on CD34(+) cell counts on the day before collection improves both the success rate and quality rate of hematopoietic stem cell collection.
    Retrospective data • Journal
    |
    CD34 (CD34 molecule)
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • plerixafor
    22d
    AALL2331: Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov)
    P2/3, N=1708, Not yet recruiting, Children's Oncology Group | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    |
    cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Darzalex (daratumumab) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • nelarabine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Purixan (mercaptopurine oral suspension) • Starasid (cytarabine ocfosfate)
    23d
    Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study (clinicaltrials.gov)
    P2, N=8, Terminated, Mayo Clinic | Trial completion date: Oct 2027 --> Feb 2025 | Active, not recruiting --> Terminated; Slow accrual
    Trial completion date • Trial termination
    |
    Imbruvica (ibrutinib) • Darzalex (daratumumab)
    29d
    A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2028 --> Nov 2027
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • JNJ-5322
    29d
    CAMMA 1: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=126, Active, not recruiting, Genentech, Inc. | Trial primary completion date: Dec 2025 --> Dec 2029 | Trial completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Darzalex (daratumumab) • dexamethasone • pomalidomide • Actemra IV (tocilizumab) • cevostamab (RG6160)
    1m
    Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=25, Completed, University of Chicago | Active, not recruiting --> Completed | N=101 --> 25
    Trial completion • Enrollment change
    |
    Darzalex (daratumumab) • carfilzomib • pomalidomide
    1m
    Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=160, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Rituxan (rituximab) • Darzalex (daratumumab)